White papersEngagement case study: Pfizer
Pfizer, in response to investor feedback, published its “Industry associations – Report on incongruencies” which provides greater transparency into how its public policy positions are aligned with the trade associations of which it is a member.
White papersPfizer case study
Pfizer has published its first climate report in line with the recommendations of the TCFD, as well as making improvements to its board gender diversity and setting new diversity and inclusion goals for the organisation.
White papersBuilding the future of innovation: Selecting cities for life sciences real estate in Europe
In the rapidly advancing realm of biotechnology and pharmaceuticals, life sciences real estate is more than bricks and mortar – it’s the enabler of innovation. Investors venturing into this specialized asset class are essentially betting on ecosystems that need real estate to grow. Think of it as the skeleton that keeps the muscles in place and the body as a whole standing. There are certain strategic parameters that can be used to select the right European cities for life sciences real estate investments. This must then be woven in with external push and pull factors that are forcing companies in the life sciences sector to adjust when it comes to their real estate footprint.
- Save articleNews
UK roundup: Pfizer subsidiary agrees £158m buy-in deal
Plus: Apollo agrees further funding arrangements with RPC schemes; JP Morgan invests in Smart Pension
White papersStewardship case study: AstraZeneca
EOS identified robust succession planning for both the CEO and the chair as integral to the achievement of a long-term strategy.
- Save article
NewsDeepSeek’s arrival increases risk for passive investors
But it provides upside for companies that use AI applications, or are keen to start doing so, according to investment experts
White papersOmicron: The Reason to Seriously Consider Getting a Third COVID-19 Vaccine Shot
Pfizer data suggests a third dose of Comirnaty (COVID-19 vaccine) appeared to increase neutralizing antibodies 25-fold against the Omicron variant, a level suggesting protective immunity against severe COVID-19.
- Save articleNews
Pfizer praised for governance engagement
[17:00 CEST 29-06] US – Pharmaceutical giant Pfizer has been commended for its decision to regularly meet with institutional investors and discuss its corporate governance.
White papersBuilding the future of innovation
Selecting cities for life sciences real estate in Europe
- Save article
NewsAsset managers’ backing of ESG resolutions falls to three-year low
ShareAction is urging asset managers to rethink voting policies seen during the last AGM season
- Save articleNews
Pension funds call on pharmas to improve vaccine distribution
They threaten to vote against executive remuneration proposals and board appointments if insufficient action is taken
- Save article
News£251m in de-risking deals as AIB converts APP, Wyeth seals buy-in
Two de-risking deals for a combined £251m were announced today, comprising the first conversion of a Legal & General Assured Payment Policy and a buy-in
- Save article
Opinion PiecesHealthcare investing: Get ready for the next pandemic
The world will have to collaborate on many fronts to ensure preparedness for the next global health crisis.
- Save articleNews
PostNL pension fund invests €400m in new SDG funds
The funds, which will be managed by Hermes and M&G, will be made available to all fiduciary clients of Kempen in the Netherlands and the UK
- Save articleNews
Wellcome Trust complains to chancellor over possible AstraZeneca deal
Foundation raises ‘major concerns’ over proposed takeover of Anglo-Swedish pharmaceutical AstraZeneca by US multinational Pfizer
- Save articleNews
UK roundup: TUI trust strikes £800m buy-in pair, Lothian names new CEO
Long-term goal for TUI Group UK Pension Trust is full insurance
- Save articleNews
Vaccine rally saves Dutch pension funds from having to cut pensions
The 90% minimum funding level will be valid until 2026, though a 95% level is needed for transition into the new DC-based system
- Save article
NewsPhilips Pensioenfonds shares in $400m class action payout
After nearly five years of litigation, both sides reach tentative agreement to settle case for $400m plus accrued interest
- Save article
Special ReportUK: Labour government seeks continuity with focus on boosting domestic investment
The Department for Work and Pensions will have its work cut out as the new Labour government starts a comprehensive pensions review
- Save article
FeaturesLong term matters: Vaccine apartheid and investors
This column last covered COVID-19 vaccine inequity in June. Since then, using The Economist’s model of “excess deaths”, there may have been more than 4m deaths globally. That means 37,700 people dying every day, arguably unnecessarily. This number comes with many caveats but it’s possible (indeed probable) that the figure could be much higher.
Search results
Copyright © 1997–2025 IPE International Publishers Limited, Registered in England, Reg No. 3233596, VAT No. 685 1784 92. Registered Office: 1 Kentish Buildings, 125 Borough High Street, London SE1 1NP
Site powered by Webvision Cloud